ArticleEndocrine2021
Associations of GDF-15 and GDF-15/adiponectin ratio with odds of type 2 diabetes in the Chinese population.
Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Different association of GDF15 and FGF21 with glycemic status and aging in the context of obesity.GeroScience · 2026Article
- Recent Insights Into Circulating Adipokines in Obesity: Systematic Review and Meta-Analysis.Obesity science & practice · 2026Review
- Unveiling GDF-15: a new frontier in combating diabetic osteoporosis.Frontiers in medicine · 2026Review
- Adipokine Levels and Glucose Metabolism Responses to the Acute Effects of High-Intensity Interval Exercise (HIIE) and Moderate Intensity Continuous Exercise (MICE) in Prediabetic Obese Men.Endocrinology, diabetes & metabolism · 2025Article
- Serum levels of GDF-15, betatrophin, TNF-α and IL-6 in diabetic patients with and without diabetic complications.Saudi medical journal · 2025Article
- Global and tissue-specific transcriptomic dysregulation in human aging: Pathways and predictive biomarkers.GeroScience · 2025Article
- Relationships between Circulating Biomarkers and Body Composition Parameters in Patients with Metabolic Syndrome: A Community-Based Study.International journal of molecular sciences · 2024Article
- The Plasma Levels of Protein Adiponectin (Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Comprehensive Role of GDF15 in Inhibiting Adipogenesis and Hyperlipidemia, Enhancing Cardiovascular Health and Alleviating Inflammation in Metabolic Disorders.Current pharmaceutical design · 2024Review
- Growth differentiation factor 15 (GDF-15) in endocrinology.Endocrine · 2023Review
- U-shaped association between serum IGF2BP3 and T2DM: A cross-sectional study in Chinese population.Journal of diabetes · 2023Article
- Growth differentiation factor-15/adiponectin ratio as a potential biomarker for metabolic syndrome in Han Chinese.Frontiers in endocrinology · 2023Article
- Associations between serum mitokine levels and outcomes in stable COPD: an observational prospective study.Scientific reports · 2022Observational
- GDF15: a potential therapeutic target for type 1 diabetes.Expert opinion on therapeutic targets · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
purposeWe elucidate the effect of Growth differentiation factor-15(GDF-15)/adiponectin ratio in improving the assessment value for odds of type 2 diabetes.
methodsCross-sectional design. A total of 405 participants (135 patients with newly diagnosed type 2 diabetes, 135 age- and sex-matched participants with prediabetes, and 135 healthy controls) were collected from Guangzhou and Dongguan, China. The serum GDF-15 and adiponectin levels were measured by ELISA and latex-enhanced immunoturbidimetry. Logistic regression analysis and restricted cubic splines were used to evaluate the associations between diabetes and the indicators.
resultsThe low level of adiponectin and high GDF-15/adiponectin ratio were significantly associated with increased odds of type 2 diabetes, but not for GDF-15. Three clusters were identified based on the K-means clustering analysis. Compared to the lowest quartiles of adiponectin, the OR and 95% CI of the highest adiponectin with type 2 diabetes was 0.24 (0.07-0.74, p trend = 0.004) after adjusting for sex, age, BMI, and DBP only in cluster 1. After adjusting for confounding factors, subjects with the highest GDF-15/adiponectin ratio quartiles had 3.9 times (OR = 3.85, 95% CI = 0.76-24.25) and 3.8 times (OR = 3.80, 95% CI = 1.02-14.68) higher odds of type 2 diabetes in cluster 2 and cluster 3, respectively. The association between the GDF-15/adiponectin ratio and type 2 diabetes was attenuated, but still remarkable (OR = 3.18, 95% CI = 1.11-10.18), in cluster 1.
conclusionsHigher GDF-15/adiponectin ratio is independently associated with increased odds of type 2 diabetes for all study populations, suggesting that the GDF-15/adiponectin ratio may be a better indicator of type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.